References
- ChanKLadeSPrinceHHarrisonSUpdate and new approaches in the treatment of Castleman diseaseJ Blood Med2016714515827536166
- GarciaACoboMPeñaPCurrent diagnosis and treatment of Castle-man’s diseaseRev Clin Esp2016216314615626749192
- NishimotoNKanakuraYAozasaKHumanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman diseaseBlood200510682627263215998837
- MohammedAJankuFQiMKurzrockRCastleman’s disease and sarcoidosis, a rare association resulting in a “mixed” response: a case reportJ Med Case Rep2015914525884809
- KoenigGStevensTMPekerDPlasmablastic microlymphoma arising in human herpesvirus-8-associated multicentric Castleman disease in a human immunodeficiency virus-seronegative patient with clinical response to anti-interleukin-6 therapyHistopathology201567693093225900626
- FajgenbaumDavidCBaggAInternational, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman diseaseBlood2017129121646165728087540
- FajgenbaumDCLiuARuthJHHV-8-Negative, idiopathic multicentric Castleman disease (iMCD): a description of clinical features and therapeutic options through a systematic literature reviewBlood2014124214861
- YuLTuMCortesJClinical and pathological characteristics of HIV- and HHV-8 negative Castleman diseaseBlood Adv20171291216581668
- van RheeFCasperCVoorheesPA phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman diseaseOncotarget201563030408301926327301
- DispenzieriAArmitageJOLoeMJThe clinical spectrum of Castleman’s diseaseAm J Hematol20128711997100222791417
- CasperCChaturvediSMunshiNAnalysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (anti-IL6 monoclonal antibody) in patients with multicentric Castleman diseaseClin Cancer Res201521194294430426124203
- MayerCLXieLBandekarRDose selection of siltuximab for multicentric Castleman’s diseaseCancer Chemother Pharmacol20157551037104525784388
- Van RheeFWongRSMunshiNSiltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trialLancet Oncol201415996697425042199
- van RheeFFayadLVoorheesPSiltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman’s diseaseJ Clin Oncol201028233701370820625121